Dr. Roser Velasco, IDIBELL principal investigator at Neuro-Oncology group and neurologist at the Neuro-Oncology Unit of ICO Hospitalet and Bellvitge University Hospital, has co-directed the writing of an international guide of recommendations on the management of neurological complications associated with CAR-T cell therapy.
Dr. Velasco has participated as an expert in neuro-oncology within the Committee for the Harmonization of Practices and Guidelines of the European Society for Blood and Marrow Transplantation (EBMT).
The guideline is intended to be a reference for hematologists and neurologists around the world that allows early identification and appropriate management of the less common but potentially very serious neurotoxicities associated with CAR-T cell therapy.
The work has been published in the latest issue of the Lancet Oncology journal, one of the most prestigious in the field of oncology, with Dr. Roser Velasco as co-lead author.
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center established in 2004 specialized in cancer, neuroscience, translational medicine, and regenerative medicine. It counts on a team of more than 1.500 professionals who, from 73 research groups, publish more than 1.400 scientific articles per year. IDIBELL is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona, and the City Council of L’Hospitalet de Llobregat.
IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).